Evaluation of the D3 dopamine receptor selective antagonist PG01037 on l-dopa-dependent abnormal involuntary movements in rats

Neuropharmacology

Volumn 56, Issue 6-7, 2009, Pages 944-955

  Kumar, Rakesh ^a   Riddle, Lindsay ^a   Griffin, Suzy A ^a   Grundt, Peter ^b   Newman, Amy Hauck ^b   Luedtke, Robert R ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

D3 dopamine receptors; Dopamine receptors; Dyskinesia; l dopa; Parkinson's Disease

Indexed keywords

BENSERAZIDE; BUSPIRONE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; LEVODOPA; N [4 [4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL]BUT 2 ENYL] 4 PYRIDIN 2 YLBENZAMIDE; PG 01037; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTAROD TEST;

ADENYLATE CYCLASE; ANIMALS; ANTIPARKINSON AGENTS; BENZAMIDES; BENZAZEPINES; CELL LINE; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MALE; MOTOR ACTIVITY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D3;

EID: 67349158011     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.01.020     Document Type: Article

References (46)

1. Bézard E., Ferry S., Mach U., Stark H., Leriche L., Boraud T., Gross C., and Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Medicine 9 (2003) 762-767
2. Blanchet P.J., Allard P., Gregoire L., Tardif F., and Bédard P.J. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Canadian Journal of Neurological Sciences 23 (1996) 189-193
3. Bordet R., Ridray S., Carboni S., Diaz J., Sokoloff P., and Schwartz J.C. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proceedings of the National Academy of Sciences of the United States of America 94 (1997) 3363-3367
4. Bordet R., Ridray S., Schwartz J.C., and Sokoloff P. Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. European Journal of Neuroscience 12 (2000) 2117-2123
5. Calon F., Morissette M., Rajput A.H., Hornykiewicz O., Bédard P.J., and Di Paolo T. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Movement Disorders 18 (2003) 241-253
6. Calon F., Rajput A.H., Hornykiewicz O., Bédard P.J., and Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiology of Disease 14 (2003) 404-416
7. Carta M., Carlsson T., Kirik D., and Björklund A. Dopamine released from 5-HT terminals is the cause of l-DOPA-induced dyskinesia in parkinsonian rats. Brain 130 (2007) 1819-1833
8. Carta M., Lindgren H.S., Lundblad M., Stancampiano R., Fadda F., and Cenci M.A. Role of striatal l-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. Journal of Neurochemistry 96 (2006) 1718-1727
9. Cenci M.A. Dopamine dysregulation of movement control in l-DOPA-induced dyskinesia. Trends in Neurosciences 30 (2007) 236-243
10. Cenci M.A., and Lundblad M. Utility of 6-hydroxydopamine lesioned rats in the preclinical screening of novel treatments for Parkinson disease. In: LeDoux M. (Ed). Animal Methods of Movement Disorders (2005), Elsevier Academic Press, San Diego, CA 193-208
11. Cenci M.A., Lee C.S., and Bjorklund A. l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylaase mRNA. European Journal of Neuroscience 10 8 (1998 Aug) 2694-2706
12. Chase T.N., Oh J.D., and Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Journal of Neurology 247 Suppl. 2 (2000) II36-II42
13. Chemel B.R., Roth B.L., Armbruster B., Watts V.J., and Nichols D.E. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berlin) 188 (2006) 244-251
14. Chu W., Tu Z., McElveen E., Xu J., Taylor M., Luedtke R.R., and Mach R.H. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorganic & Medicinal Chemistry 13 (2005) 77-87
15. Clarke C.E., Boyce S., Robertson R.G., Sambrook M.A., and Crossman A.R. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of MPTP. Journal of Neurological Sciences 90 (1989) 307-314
16. Cliffe I.A. A retrospect on the discovery of WAY-100635 and the prospect for improved 5-HT(1A) receptor PET radioligands. Nuclear Medicine & Biology 27 (2000) 441-447
17. Collins G.T., Calinski D.M., Newman A.H., Grundt P., and Woods J.H. Food restriction alters pramipexole-induced yawning, hypothermia, and locomotor activity in rats: evidence for sensitization of dopamine D2 receptor-mediated effects. Journal of Pharmacology and Experimental Therapeutics 325 (2008) 691-697
18. Collins G.T., Newman A.H., Grundt P., Rice K.C., Husbands S.M., Chauvignac C., Chen J., Wang S., and Woods J.H. Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology (Berlin) 193 (2007) 159-170
19. Collins G.T., Witkin J.M., Newman A.H., Svensson K.A., Grundt P., Cao J., and Woods J.H. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. Journal of Pharmacology and Experimental Therapeutics 314 (2005) 310-319
20. Dekundy A., Lundblad M., Danysz W., and Cenci M.A. Modulation of l-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behavioural Brain Research 179 (2007) 76-89
21. Delfino M., Kalisch R., Czisch M., Larramendy C., Ricatti J., Taravini I.R., Trenkwalder C., Murer M.G., Auer D.P., and Gershanik O.S. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology 32 (2007) 1911-1921
22. Deumens R., Blokland A., and Prickaerts J. Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostraital pathway. Experimental Neurology 175 (2002) 303-317
23. Fabbrini G., Brotchoie J.M., Grandas F., Nomoto M., and Goeta C.G. Levadopa-induced dyskinesia. Movement Disorders 22 (2007) 1379-1389
24. Fiorentini C., Busi C., Gorruso E., Gotti C., Spano P., and Missale C. Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization. Molecular Pharmacology 74 (2008) 59-69
25. Grandas F., Galiano M.L., and Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. Journal of Neurology 246 (1999) 1127-1133
26. Grundt P., Carlson E.E., Cao J., Bennett C.J., McElveen E., Taylor M., Luedtke R.R., and Newman A.H. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Journal of Medicinal Chemistry 48 (2005) 839-848
27. Grundt P., Prevatt K.M., Cao J., Taylor M., Floresca C.Z., Choi J.-K., Jenkins B.G., Luedtke R.R., and Newman A.H. Heterocyclic analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. Journal of Medicinal Chemistry 50 (2007) 4135-4146
28. Guigoni C., Aubert I., Li Q., Gurevich V.V., Benovic J.L., Ferry S., Mach U., Stark H., Leriche L., Håkansson K., Bioulac B.H., Gross C.E., Sokoloff P., Fisone G., Gurevich E.V., Bloch B., and Bezard E. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism & Related Disorders 11 Suppl. 1 (2005) S25-S29
29. Hermanowicz N. Drug therapy for Parkinson's disease. Seminars in Neurology 27 (2007) 97-105
30. Hsu A., Togasaki D.M., Bezard E., Sokoloff P., Langston J.W., Di Monte D.A., and Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. Journal of Pharmacology and Experimental Therapeutics 311 (2004) 770-777
31. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Annals of Neurology 47 (2000) S90-S104
32. Luedtke R.R., and Mach R.H. Progress in developing D3 dopamine receptor ligands as potential therapeutic agents for neurological and neuropsychiatric disorders. Current Pharmaceutical Design 9 (2003) 643-671
33. 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse 38 (2000) 438-449
34. Lundblad M., Anderson M., Winkler C., Kirik D., Wierup N., and Cenci M.A. Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson's disease. European Journal of Neuroscience 15 (2002) 120-132
35. Lundblad M., Vaudano E., and Cenci M.A. Cellular and behavioral effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia. Journal of Neurochemistry 84 (2003) 1398-1410
36. Martel J.C., Leduc N., Ormière A.M., Faucillon V., Danty N., Culie C., Cussac D., and Newman-Tancredi A. WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. European Journal of Pharmacology 574 (2007) 15-19
37. Nutt J.G. Motor fluctuations and dyskinesia in Parkinson's disease. Parkinsonism & Related Disorders 8 (2001) 101-108
38. Sánchez-Pernaute R., Jenkins B.G., Choi J.K., Iris Chen Y.C., and Isacson O. In vivo evidence of D(3) dopamine receptor sensitization in parkinsonian primates and rodents with l-dopa-induced dyskinesias. Neurobiology of Disease 27 (2007) 220-227
39. Schallert T., and Tillerson J.L. Intervention strategies for degeneration of dopamine neurons in parkinsonism: optimizing behavioral assessment of outcome. In: Emerich D.F., Dean III R.L., and Sandberg P.R. (Eds). Central Nervous System Diseases: Innovative Models of CNS Diseases from Molecule to Therapy (2000), Humana Press, New Jersey 131-151
40. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
41. Schwartz J.C., Diaz J., Bordet R., Griffon N., Perachon S., Pilon C., Ridray S., and Sokoloff P. Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence. Brain Research Reviews 26 (1998) 236-242
42. Schwartz J.C., Ridray S., Bordet R., Diaz J., and Sokoloff P. D1/D3 receptor relationships in brain coexpression, coactivation, and coregulation. Advances in Pharmacology 42 (1998) 408-411
43. Shi L.H., Woodward D.J., Luo F., Anstrom K., Schallert T., and Chang J.Y. High-frequency stimulation of the subthalamic nucleus reverses limb-use asymmetry in rats with unilateral 6-hydroxydopamine lesions. Brain Research 1013 (2004) 98-106
44. Suzuki M., Hurd Y.L., Sokoloff P., Schwartz J.C., and Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Research 779 (1998) 58-74
45. Ungerstedt U. 6-Hhydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: the turning syndrome. Pharmacological & Therapeutics. Part B: General & Systematic Pharmacology 1976 (1976) 37-40
46. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. European Journal of Pharmacology 5 (1968) 107-110